Jacobus Pharmaceutical Company Inc.

FDA Regulatory Profile

Jacobus Pharmaceutical Company Inc. appears in FDA public data with 1 recall — including 1 Class I (most serious) —, 0 510(k) clearances, 0 FDA inspections, and 0 compliance actions on record. Its most recent recall (D-0008-2022, Class I) was initiated on September 9, 2021.

Summary

Total Recalls
1 (1 Class I)
510(k) Clearances
0
Inspections
0
Compliance Actions
0

Recent Recalls

NumberClassProductDate
D-0008-2022Class IRuzurgi (amifampridine) Tablets 10 mg, packaged in 100-count bottles, Rx only, Manufactured by: JacoSeptember 9, 2021